$MBRX
Moleculin Biotech, Inc.

2019 Q3 Form 10-Q Financial Statement

#000165961719000144 Filed on August 16, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.670M $1.480M $1.220M
YoY Change 33.6% 21.31% 52.5%
% of Gross Profit
Research & Development $2.785M $2.099M $4.231M
YoY Change 109.08% -50.39% 721.55%
% of Gross Profit
Depreciation & Amortization $51.00K $49.00K $7.000K
YoY Change 363.64% 600.0% 40.0%
% of Gross Profit
Operating Expenses $4.508M $3.632M $5.458M
YoY Change 73.99% -33.46% 313.48%
Operating Profit -$4.508M -$3.632M -$5.458M
YoY Change 73.99% -33.46% 313.48%
Interest Expense $130.0K $2.410M $330.0K
YoY Change -77.19% 630.3%
% of Operating Profit
Other Income/Expense, Net $5.000K $0.00 -$1.000K
YoY Change -123.81% -100.0%
Pretax Income -$4.374M -$1.220M -$5.130M
YoY Change 114.41% -76.22% 50.0%
Income Tax -$229.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.145M -$1.221M -$5.125M
YoY Change 103.39% -76.18% 49.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$547.5K -$172.6K -$1.190M
COMMON SHARES
Basic Shares Outstanding 45.20M shares 45.19M shares 25.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.41M $18.70M $11.72M
YoY Change 79.19% 59.56% 26.43%
Cash & Equivalents $15.41M $18.70M $11.72M
Short-Term Investments
Other Short-Term Assets $3.180M $1.510M $1.170M
YoY Change 318.42% 29.06% 44.44%
Inventory
Prepaid Expenses $1.507M
Receivables $316.0K
Other Receivables
Total Short-Term Assets $18.59M $20.20M $12.89M
YoY Change 98.57% 56.7% 27.88%
LONG-TERM ASSETS
Property, Plant & Equipment $358.0K $401.0K $26.00K
YoY Change -8.44% 1442.31% 30.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.81M $11.65M $11.17M
YoY Change 2.37% 4.28% 0.05%
TOTAL ASSETS
Total Short-Term Assets $18.59M $20.20M $12.89M
Total Long-Term Assets $11.81M $11.65M $11.17M
Total Assets $30.40M $31.85M $24.07M
YoY Change 45.45% 32.36% 13.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.188M $1.257M $1.676M
YoY Change 306.11% -25.0% 157.85%
Accrued Expenses $1.111M $1.390M $1.839M
YoY Change -39.12% -24.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.12M $9.591M $4.116M
YoY Change 255.35% 133.02% 124.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $170.0K $3.200M
YoY Change -89.29% -94.69% 2033.33%
Total Long-Term Liabilities $300.0K $170.0K $3.200M
YoY Change -89.29% -94.69% 2033.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.12M $9.591M $4.116M
Total Long-Term Liabilities $300.0K $170.0K $3.200M
Total Liabilities $11.42M $9.762M $7.318M
YoY Change 92.6% 33.4% 269.6%
SHAREHOLDERS EQUITY
Retained Earnings -$35.80M -$31.60M -$21.50M
YoY Change 51.69% 46.98% 155.07%
Common Stock $54.72M $53.69M $38.27M
YoY Change 42.06% 40.27% 38.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.98M $22.09M $16.75M
YoY Change
Total Liabilities & Shareholders Equity $30.40M $31.85M $24.07M
YoY Change 45.45% 32.36% 13.26%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$4.145M -$1.221M -$5.125M
YoY Change 103.39% -76.18% 49.68%
Depreciation, Depletion And Amortization $51.00K $49.00K $7.000K
YoY Change 363.64% 600.0% 40.0%
Cash From Operating Activities -$3.330M -$5.340M -$3.460M
YoY Change 18.09% 54.34% 79.27%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K $0.00
YoY Change -96.55%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$10.00K $0.00
YoY Change -96.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 15.28M 2.060M
YoY Change 641.75% -11.21%
NET CHANGE
Cash From Operating Activities -3.330M -5.340M -3.460M
Cash From Investing Activities -10.00K -10.00K 0.000
Cash From Financing Activities 50.00K 15.28M 2.060M
Net Change In Cash -3.290M 9.930M -1.400M
YoY Change 5.79% -809.29% -458.97%
FREE CASH FLOW
Cash From Operating Activities -$3.330M -$5.340M -$3.460M
Capital Expenditures -$10.00K -$10.00K $0.00
Free Cash Flow -$3.320M -$5.330M -$3.460M
YoY Change 31.23% 54.05% 79.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q2 mbx Licensing Agreement Term
LicensingAgreementTerm
P3Y
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
CY2017Q3 mbx Classof Warrantor Right Agreement Period
ClassofWarrantorRightAgreementPeriod
P12M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37758
dei Entity Registrant Name
EntityRegistrantName
MOLECULIN BIOTECH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
300-5160
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45197048 shares
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18695000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7134000 USD
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1507000 USD
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
840000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
20202000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
7974000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
401000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463000 USD
CY2019Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2018Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 USD
CY2019Q2 us-gaap Assets
Assets
31854000 USD
CY2018Q4 us-gaap Assets
Assets
19585000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1257000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1246000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1390000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2452000 USD
CY2019Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6944000 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
180000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9591000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3878000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
171000 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
107000 USD
CY2019Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1328000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
9762000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
5313000 USD
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45197048 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45197048 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28528663 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28528663 shares
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
45000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
53643000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40564000 USD
CY2019Q2 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
22000 USD
CY2018Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
35000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31618000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26356000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2099000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
22092000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31854000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19585000 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4231000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5031000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5469000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1484000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1220000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3075000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2611000 USD
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000 USD
CY2018Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
3632000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
5458000 USD
us-gaap Operating Expenses
OperatingExpenses
8203000 USD
us-gaap Operating Expenses
OperatingExpenses
8095000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3632000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5458000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8203000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8095000 USD
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2407000 USD
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-331000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2936000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1040000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 USD
CY2018Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7052000 USD
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24617372 shares
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42393031 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25888931 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35765790 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7052000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 USD
CY2018Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
6000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
6000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1223000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5119000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5275000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7046000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7052000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
666000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
581000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2936000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1040000 USD
mbx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
6000 USD
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
0 USD
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
1000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
667000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
582000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
866000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1097000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
937000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9194000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6274000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1557000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19240000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
10269000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20802000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10284000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-13000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7134000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11561000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4008000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7714000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18695000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11722000 USD
us-gaap Interest Paid Net
InterestPaidNet
1000 USD
us-gaap Interest Paid Net
InterestPaidNet
1000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
15000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
617000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2019Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-11000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14682000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
302000 USD
CY2019Q2 mbx Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
4731000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
318000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
CY2019Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-2000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
22092000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17118000 USD
CY2018Q1 mbx Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
15000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
809000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5122000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
242000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
20570000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
232000 USD
mbx Number Of Drug Technologies
NumberOfDrugTechnologies
3 technology
mbx Numberof Drug Candidates
NumberofDrugCandidates
6 candidate
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
339000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000 USD
CY2018Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
6000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
16748000 USD
mbx Numberof Drugsin Clinical Trials
NumberofDrugsinClinicalTrials
3 drug
mbx Numberof Clinical Trials
NumberofClinicalTrials
4 clinicalTrial
mbx Number Of Other Drug Development Projects
NumberOfOtherDrugDevelopmentProjects
5 project
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31600000 USD
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
200000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6538515 shares
CY2019Q2 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
31000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13427998 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Reclassifications - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.</span>
CY2019Q2 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
678000 USD
CY2018Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
492000 USD
CY2019Q2 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
420000 USD
CY2018Q4 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
95000 USD
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
116000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91000 USD
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
1147000 USD
CY2019Q2 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
18000 USD
CY2018Q4 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
400000 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
92000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1390000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2452000 USD
CY2019Q2 mbx Shares Authorized
SharesAuthorized
105000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 mbx Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction
SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction
20000000.0 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2794000 shares
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.78
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.61
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M4D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21200000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
45000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.80
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.15
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000 shares
mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
0.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2814000 shares
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.80
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M1D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6800000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
839333 shares
CY2019Q2 mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
2.11
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6800000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
318000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
339000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2300000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
10000.00 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
666000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
581000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
45000 shares
CY2019Q2 mbx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregated Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue
40000.00 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2600000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M10D
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2019Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2018Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Operating Lease Cost
OperatingLeaseCost
20000.00 USD
us-gaap Variable Lease Cost
VariableLeaseCost
10000.00 USD
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000.00 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
30000.00 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
10000.00 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
26000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
53000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
55000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
55000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
253000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
206000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
48000 USD
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
CY2016Q2 mbx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
53000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
54000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
55000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
56000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2018Q2 mbx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
mbx Employee Agreements Special Termination Benefits Numberof Employees
EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees
7 employee
mbx Employee Agreements Termination Benefits Provided To Key Employees Aggregate Amount
EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
1300000 USD

Files In Submission

Name View Source Status
0001659617-19-000144-index-headers.html Edgar Link pending
0001659617-19-000144-index.html Edgar Link pending
0001659617-19-000144.txt Edgar Link pending
0001659617-19-000144-xbrl.zip Edgar Link pending
a2019q2ex311-xnextgen.htm Edgar Link pending
a2019q2ex312-xnextgen.htm Edgar Link pending
a2019q2ex321-xnextgen.htm Edgar Link pending
a2019q2ex322-xnextgen.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbx-20190630.htm Edgar Link pending
mbx-20190630.xsd Edgar Link pending
mbx-20190630_cal.xml Edgar Link unprocessable
mbx-20190630_def.xml Edgar Link unprocessable
mbx-20190630_g1.jpg Edgar Link pending
mbx-20190630_htm.xml Edgar Link completed
mbx-20190630_lab.xml Edgar Link unprocessable
mbx-20190630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending